Currently, we are developing two experimental products for the treatment of mild to moderate osteoarthritis due to dysplasia or trauma. Our ADStem preparation contains allogeneic stem cells for dogs and AHStem is composed of allogeneic stem cells for horses. ADStem is currently being submitted for approval as a licenced product by the European Medicines Agency.